Researchers are combining experience in chemical synthesis and nanoparticle engineering with their knowledge of cancer development to design future therapies.
Simmons has pioneered a new patient-derived organoid model of lower-grade glioma capable of identifying biomarker-guided therapeutic strategies poised for clinical translation.